📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
1,000+ announcements match the current filters (relevance ≥ 5).
Glenmark Receives US FDA EIR for Goa Facility with VAI Classification
Glenmark Pharmaceuticals has received an Establishment Inspection Report (EIR) from the U.S. FDA for its formulations manufacturing facility located in Goa, India. The inspection, which was carried out from June 22 to June 30, 2026, concluded with a Voluntary Action Indicated (VAI) status. This classification confirms that while objectionable conditions were observed, they do not meet the threshold for regulatory or administrative action, effectively clearing the facility. The successful closure removes regulatory overhang on product approvals and exports from this critical site.
Confidence: HIGH
What changedThe US FDA inspection of the Goa formulations facility conducted in June 2026 has officially closed with a VAI classification.
Why it mattersA VAI classification clears the Goa facility for commercial shipments and clears hurdles for pending new drug applications targeting the US market.
Inspection start date: June 22, 2026Inspection end date: June 30, 2026Total manufacturing facilities: 11
📅 Short termPositive sentiment relief as the facility avoids an Official Action Indicated (OAI) or warning letter, removing an operational overhang.
📈 Long termEnsures uninterrupted product supply and preserves the US product launch pipeline, supporting the company's Glenmark 3.0 US revival target.
Key Highlights
US FDA issues EIR with Voluntary Action Indicated (VAI) classification for the Goa formulations plant
Inspection concluded was conducted between June 22, 2026 and June 30, 2026
Goa facility represents one of Glenmark's 11 manufacturing facilities globally
👀 What to Watch
Track upcoming US ANDA approvals and product launch timelines originating from the Goa facility over the subsequent quarters.
MCC-Om JV Wins ₹32.18 Cr Irrigation Work Order Under Gosikhurd Project
Om Infra Limited announced that its joint venture, MCC-Om (JV), has received a ₹32.18 crore work order from the Vidarbha Irrigation Development Corporation (VIDC), Maharashtra. The contract entails constructing a Lift Irrigation Scheme to feed the Ghodazari Tank under the Gosikhurd Project. The project is slated for completion within 12 calendar months, including the monsoon period. The contract value represents roughly 6.2% of the company's TTM revenue of ₹520 crore.
Confidence: HIGH
What changedMCC-Om JV formalized an agreement and received the official work order dated September 18, 2026, for a lift irrigation scheme in Maharashtra.
Why it mattersAdds ₹32.18 crore to the JV order book, reinforcing Om Infra's presence in regional water infrastructure projects, though its financial impact on standalone revenue depends on Om Infra's exact JV stake.
Order value: ₹32,17,72,860/-Execution timeline: 12 Calendar MonthsForest land involved: 0.941 haOrder value vs TTM revenue: ~6.2%
📅 Short termProvides incremental revenue visibility over the next four quarters as civil and mechanical work commences.
📈 Long termLimited; aligns with the company's core focus on water resources and irrigation EPC, but is relatively small compared to historical annual revenue.
⚠ Risk flags
- Execution risks within forest land (0.941 ha) dependent on forest division coordination
- JV equity share and revenue split not explicitly disclosed in the filing
Key Highlights
Contract value awarded to MCC-Om (JV) is ₹32,17,72,860/-
Awarded by the Executive Engineer, Ghodazari Canal Division, Nagbhid under VIDC, Maharashtra
Execution timeline set to 12 calendar months including the monsoon season
Scope includes working across 0.941 ha of designated forest land requiring coordination with forest authorities
👀 What to Watch
Monitor execution progress over the 12-month period and watch for JV share breakdown disclosure in subsequent filings.
Lemon Tree Hotels Receives No-Objection from NSE and BSE for Composite Scheme of Arrangement
Lemon Tree Hotels Limited has received 'no objection' from the NSE and 'no adverse observations' from the BSE on September 22, 2026, for its proposed draft Composite Scheme of Arrangement. The scheme involves Lemon Tree Hotels, Fleur Hotels Limited, and six other group entities. This follows earlier approvals, including Competition Commission of India (CCI) clearance received on April 7, 2026. The stock exchange observation letters remain valid for six months, within which the company must submit the scheme petition before the National Company Law Tribunal (NCLT).
Confidence: HIGH
What changedStock exchanges (NSE and BSE) cleared the proposed Composite Scheme of Arrangement without adverse remarks, permitting the company to approach the NCLT.
Why it mattersSecuring exchange approvals clears a major regulatory hurdle toward corporate restructuring and potential direct listing of Fleur Hotels, clarifying group corporate holding structure.
Exchange NOC approval date: September 22, 2026Observation letter validity: 6 monthsPost-NCLT listing timeline for Fleur Hotels: 60 daysCompany TTM revenue context: Rs 1444 Cr
📅 Short termNeutral to mildly positive procedural milestone; equity trading sentiment will likely focus on subsequent NCLT filings and valuation/swap ratio details.
📈 Long termCould streamline asset ownership and corporate structure across Fleur Hotels and Lemon Tree, potentially unlocking value upon completion and listing.
⚠ Risk flags
- Subject to approvals from NCLT, shareholders, and creditors
- Strict regulatory compliance required on disclosures and swap valuation
Key Highlights
Received NSE 'no objection' and BSE 'no adverse observations' letters dated September 22, 2026
Scheme involves Fleur Hotels Limited and six transferor companies under Sections 230 to 232 of Companies Act, 2013
Observation letters are valid for a period of 6 months to file the petition before the NCLT
Follows earlier clearance from the Competition Commission of India (CCI) approved on April 7, 2026
Fleur Hotels Limited is mandated to commence trading within 60 days of receipt of the final NCLT order
👀 What to Watch
Track the filing of the formal scheme petition with the NCLT within the 6-month window and watch for subsequent shareholder/creditor meeting notices.
Orchid Pharma Acquires Leased Land at Patibulum, Resolving Dispute with DBS Bank
Orchid Pharma has completed the purchase of land situated at Patibulum Village, Kancheepuram District, Tamil Nadu. This acquisition concludes the erstwhile lease arrangement and permanently closes the company's dispute with DBS Bank India Limited regarding the property. The transaction extinguishes DBS Bank's rights and secures clear land ownership for Orchid Pharma, though the financial purchase consideration was not disclosed.
Confidence: MEDIUM
What changedOrchid Pharma has transitioned from leaseholder to absolute owner of the Patibulum property, terminating DBS Bank's interest.
Why it mattersEliminates lease rental dispute risks and legal overhang associated with DBS Bank, providing operational certainty for the site.
Purchase consideration: not disclosedEarlier dispute intimation date: June 06, 2025TTM Net Worth context: ₹1,370 Cr
📅 Short termPositive sentiment from clearing up legacy banking disputes, though immediate financial impact remains unquantified.
📈 Long termEnsures uninterrupted ownership of land assets, eliminating recurring lease liabilities or repossession risks.
⚠ Risk flags
- Financial outflow and valuation terms of the land purchase were not disclosed
Key Highlights
Purchased leased land property situated at Patibulum Village, Kancheepuram District, Tamil Nadu
Marks conclusion of dispute referenced in earlier intimation dated June 06, 2025
Results in complete cessation of DBS Bank India Limited's rights and interest in the property
Purchase consideration and financial deal size were not disclosed in the filing
👀 What to Watch
Monitor upcoming quarterly financial filings to assess the cash outflow/capex spent on the land purchase and its impact on Orchid Pharma's debt and balance sheet.
Mold-Tek Packaging Shareholders Approve Bonus Issue & Final Dividend of ₹3/Share
Mold-Tek Packaging Limited announced the voting results of its 29th Annual General Meeting held on September 21, 2026. Shareholders approved all 10 resolutions with requisite majorities, including the declaration of a final dividend of ₹3 per share (60% on face value of ₹5) for FY26. Key corporate actions passed also include the issuance of bonus shares and an increase in authorized share capital. Total valid votes cast stood at 15,824,723 representing 47.62% of outstanding shares.
Confidence: HIGH
What changedShareholders officially approved FY26 financial statements, a ₹3/share final dividend, executive appointments/remunerations, capital increase, and a bonus share issuance.
Why it mattersEnables capital restructuring through bonus shares, satisfies shareholder return expectations with the final dividend, and formalizes leadership mandates.
Final Dividend per Share: Rs.3/- (60%)Face Value per Share: Rs.5/-Total Shareholders on Record Date: 65463Total Votes Polled: 15824723Turnout / Polled % of Outstanding: 47.6234%
📅 Short termBonus share approval provides positive sentiment; investors will watch for the announcement of the bonus record date and ex-date.
📈 Long termLimited direct structural impact beyond expanded equity base from bonus shares and formalisation of leadership compensation and board composition.
Key Highlights
Final dividend of ₹3 (60%) per equity share of face value ₹5 declared and approved
Approval granted for the issue of Bonus Shares (Resolution 10 passed with ~100% votes in favour)
Increase in Authorized Capital and alteration of Capital Clause approved (15,824,613 votes in favour)
47.62% of outstanding shares (15,824,723 votes) were polled across 65,463 shareholders as of record date September 14, 2026
👀 What to Watch
Track the upcoming corporate announcement for the record date and entitlement ratio regarding the approved bonus share issue, as well as the dividend payout schedule.
Arvind SmartSpaces Crosses ₹500 Cr+ Bookings in Bengaluru Project within 30 Days of Launch
Arvind SmartSpaces announced that its newly launched premium vertical residential project, 'Arvind Sylva – The Green Reserve' in Bengaluru, achieved bookings exceeding ₹500 crore within 30 days of launch. This represents an absorption of ~60% by value against the project's total estimated topline potential of ~₹860 crore. The bookings figure of >₹500 crore is exceptionally large relative to the company's annual business, surpassing its full-year TTM revenue of ₹491 crore (~102%). Spread across 4.7 acres with ~375 residences, the outright project was originally acquired in February 2026.
Confidence: HIGH
What changedArvind SmartSpaces launched its largest vertical project 'Arvind Sylva' in Bengaluru and secured over ₹500 crore in sales bookings within the first month.
Why it mattersThe ₹500+ crore booking value exceeds the company's entire TTM revenue (₹491 crore), proving strong sales velocity in premium high-rise developments outside its home market of Gujarat.
Bookings achieved (30 days): Rs. 500 Cr+Bookings vs TTM revenue: ~102%Total project topline potential: ~Rs 860 CrInventory absorption by value: ~60%Project size: 4.7 acres (~375 units)
📅 Short termStrong operational bookings will boost advance collections and operating cash flows, significantly supporting upcoming quarterly operational updates.
📈 Long termValidates the company's geographical diversification into Bengaluru's high-rise market and outright acquisition strategy, building strong visibility for revenue over the next 3-4 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution and construction delays typical in high-rise vertical developments (36-48 month cycle)
- Revenue recognition depends on construction progress and completion timelines
Key Highlights
Achieved bookings exceeding ₹500 Cr within 30 days of launch, representing ~60% inventory absorption by value
Project acquired on outright basis in February 2026 with a total topline potential of ~₹860 Cr
Development covers 4.7 acres comprising around 375 premium residential units with 70%+ open spaces
Marks the company's largest vertical development project launched to date
👀 What to Watch
Monitor quarterly cash collections and milestones for project execution over the next 36-48 months, as revenue recognition will depend on construction progress under Ind AS 115.
Premier Energies Approves Enabling Resolution for Up to ₹5,000 Cr Capital Raise at 31st AGM
Premier Energies has concluded its 31st Annual General Meeting with shareholders passing all 8 resolutions, notably approving an enabling resolution to raise up to ₹5,000 crore via equity or convertible securities (passed with 99.25% votes in favour). The ₹5,000 crore fundraising limit represents approximately 12.2% of its ₹40,889 crore market cap and 59% of TTM revenue (₹8,466 crore), potentially funding its multi-GW cell and module expansion plans. Shareholders also approved the confirmation of total ₹1.00 per share interim dividend (₹0.25 and ₹0.75 already paid) as final dividend, and re-appointed key management including Managing Director Chiranjeev Singh Saluja and Chairman Surenderpal Singh Saluja.
Confidence: HIGH
What changedShareholders officially passed all AGM resolutions, unlocking enabling approval to raise up to ₹5,000 crore in fresh capital and confirming key executive re-appointments.
Why it mattersThe ₹5,000 crore headroom provides the financial backing needed for massive ongoing capacity expansions (targeting >7 GW cell and >9 GW module capacity) without over-leveraging the balance sheet.
Fundraising limit approved: ₹5,000 CroresFundraise vs Market Cap: ~12.2%Fundraise vs TTM Revenue: ~59.1%Total final dividend confirmed: ₹1.00 per shareVoting approval for fundraise: 99.25%
📅 Short termPositive sentiment from shareholder clearance of growth capital, though market focus will quickly shift to the timing and terms of any actual issue.
📈 Long termSecuring capital approval supports the long-term roadmap to scale integrated manufacturing to >7 GW cells and >9 GW modules by FY27.
⚠ Risk flags
- Equity dilution risk if the ₹5,000 crore enabling resolution is fully tapped via new shares
- Execution and raw material reliance risks associated with large-scale multi-gigawatt solar expansion
Key Highlights
Shareholders approved capital raise limit not exceeding ₹5,000 crore with 99.25% votes in favour
Confirmed ₹1.00 total dividend per share (₹0.25 first interim and ₹0.75 second interim already paid) as final dividend
Managing Director Chiranjeev Singh Saluja re-appointed with 96.65% majority support
All 8 resolutions passed at the AGM held on September 21, 2026, with 3,35,616 total shareholders on record
👀 What to Watch
Track board announcements for actual fundraising moves (such as QIP launches, issue pricing, and potential dilution), as well as progress on planned cell/module expansions toward FY27 targets.
Visdem Technosys CFO Mahesh Singh Masani Resigns Effective September 22, 2026
Visdem Technosys Limited (formerly Kundan Edifice Limited) announced the resignation of its Chief Financial Officer and Key Managerial Personnel, Mr. Mahesh Singh Masani. The resignation takes effect from the close of business hours on September 22, 2026. The departing CFO cited personal and professional goals in his resignation letter. The company has not yet named a replacement for the CFO position.
Confidence: HIGH
What changedMr. Mahesh Singh Masani stepped down as CFO and KMP of Visdem Technosys Limited effective September 22, 2026.
Why it mattersThe CFO is a critical Key Managerial Personnel role responsible for financial oversight, compliance, and reporting; an abrupt vacancy requires quick succession planning.
Effective resignation date: 22nd September, 2026Successor named: not disclosed
📅 Short termShort-term focus will be on the operational handover and the announcement of an interim or permanent CFO.
📈 Long termLimited, provided a suitable and qualified successor is appointed promptly to maintain financial governance.
⚠ Risk flags
- Interim leadership vacuum in the finance function until a new CFO is appointed
Key Highlights
CFO Mahesh Singh Masani resigned effective close of business hours on September 22, 2026
Departure cited personal and professional goals as the underlying reason
Outgoing executive offered support for the handover process over the coming weeks
Filing made under Regulation 30 read with Schedule III of SEBI LODR Regulations, 2015
👀 What to Watch
Track subsequent exchange filings for the appointment of a new Chief Financial Officer to evaluate leadership continuity and transition.
Prostarm Wins Rs 3.67 Cr UPS Order from Rayzon Energy
Prostarm Info Systems Limited has secured a purchase order valued at Rs 3.67 Crores from Rayzon Energy Private Limited. The contract covers the supply, installation, testing, and commissioning (SITC) of an aggregate 2900 kVA UPS system (2400 kVA and 500 kVA). Delivery is scheduled within a short turnaround period of 5 to 6 weeks from the date of the purchase order. Relative to the company's TTM revenue of Rs 357 Crores, this order represents approximately 1.03%, reflecting a routine flow of business.
Confidence: HIGH
What changedProstarm secured a Rs 3.67 Crore domestic purchase order for 2900 kVA UPS systems from Rayzon Energy.
Why it mattersDemonstrates ongoing demand in its core power solutions business, although the order is small relative to annual revenue (~1%).
Order value: Rs. 3.67 CroresOrder vs TTM revenue: ~1.03%Total capacity ordered: 2900 kVADelivery timeline: Within 5–6 weeks
📅 Short termLimited operational or market impact as the contract size is modest relative to quarterly revenue (Rs 76 Cr in Jun 2026).
📈 Long termLimited; reflects routine commercial operations within its regular power solutions segment.
⚠ Risk flags
- Tight execution timeframe of 5–6 weeks
- Warranty obligations extending up to 5 years for UPS and 3 years for batteries
Key Highlights
Purchase order value of Rs 3.67 Crores from Rayzon Energy Private Limited
Scope includes SITC of aggregate 2900 kVA UPS systems (2400 kVA and 500 kVA) with batteries and accessories
Strict execution timeline requiring delivery within 5 to 6 weeks
Warranty coverage includes 5 years for UPS systems and 3 years for batteries
👀 What to Watch
Track execution and revenue realization across the next two quarters given the 5–6 week delivery timeline, and monitor working capital management.
CRISIL Reaffirms Seamec's Ratings at 'CRISIL A+/Stable' and 'CRISIL A1' for Rs 863 Cr Bank Facilities
CRISIL Ratings has reaffirmed Seamec Limited's long-term rating at 'CRISIL A+/Stable' and short-term rating at 'CRISIL A1' across total bank facilities of Rs 863 crore. Importantly, the agency removed both ratings from 'Rating Watch with Developing Implications', signaling normalized credit visibility. The rated facilities of Rs 863 crore represent approximately 84% of Seamec's TTM revenue of Rs 1,024 crore, covering both existing debt (Rs 297 crore) and potential fleet expansion borrowing needs.
Confidence: HIGH
What changedCRISIL resolved its 'Rating Watch with Developing Implications' and reaffirmed Seamec's credit ratings with a 'Stable' long-term outlook.
Why it mattersRemoval from rating watch removes credit overhang and ensures the company retains stable borrowing terms and competitive interest rates for bank facilities totaling Rs 863 crore.
Total Bank Loan Facilities Rated: Rs. 863 CroreLong Term Rating: Crisil A+/ StableShort Term Rating: Crisil A1Rated facilities vs TTM Revenue: ~84.3%
📅 Short termPositive sentiment from the removal of the rating watch, providing borrowing clarity for ongoing working capital and vessel finance.
📈 Long termMaintains solid banking access to support planned fleet additions and debt-funded vessel acquisitions without an increase in credit spreads.
⚠ Risk flags
- High client concentration with primary customer ONGC
- Execution and leverage risk as planned vessel acquisitions may scale debt closer to rated limits
Key Highlights
CRISIL reaffirmed Long Term Rating at 'Crisil A+/ Stable' and removed it from 'Rating Watch with Developing Implications'
Short Term Rating reaffirmed at 'Crisil A1' and removed from 'Rating Watch with Developing Implications'
Total bank loan facilities rated stand at Rs 863 Crore
Rated bank facilities represent ~84% of TTM revenue (Rs 1,024 Cr) and ~70% of net worth (Rs 1,229 Cr)
👀 What to Watch
Monitor upcoming quarterly results and debt uptake for vessel acquisitions to verify leverage remains manageable within current rating headroom.
Promoters Seek Pre-Clearance to Sell Up to 4.42 Lakh Shares in Magson Retail
Magson Retail and Distribution Limited received and approved pre-clearance applications under SEBI Insider Trading Regulations from two promoters to sell their shareholdings. Promoter Rajesh Emmanuel Francis proposes to sell his entire holding of up to 2,81,100 shares, and promoter Manish Shivnarayan Pancholi proposes to sell up to 1,61,100 shares (his entire holding). At the referenced market price of INR 177.00 per share, the combined proposed sale of 4,42,200 shares is valued at approximately INR 7.83 Cr. Trades are proposed to be executed via open market within 7 days of approval.
Confidence: HIGH
What changedTwo company promoters have sought and received pre-clearance approval to liquidate up to 100% of their individual shareholdings (totaling 4.42 lakh shares).
Why it mattersPromoter selling—especially liquidating full individual stakes—can increase open market supply and often raises market scrutiny regarding insider sentiment and future promoter commitment.
Rajesh Francis proposed sale: 2,81,100 Equity SharesManish Pancholi proposed sale: 1,61,100 Equity SharesCombined proposed sale volume: 4,42,200 Equity SharesApplication reference price: INR 177.00/- per Equity ShareApproximate transaction value: ~Rs 7.83 Cr
📅 Short termPotential selling overhang on the stock over the next 7 trading days as 4.42 lakh shares could be offloaded via open exchange trades.
📈 Long termLimited operational impact, but complete exit by named individual promoters reduces aggregate insider ownership (promoter holding was already down to ~36.5% as of April 2026).
⚠ Risk flags
- Promoter stake dilution/exit
- Short-term stock supply pressure in the open market
Key Highlights
Promoter Rajesh Emmanuel Francis applied to sell up to 2,81,100 equity shares (reducing holding to NIL)
Promoter Manish Shivnarayan Pancholi applied to sell up to 1,61,100 equity shares (reducing holding to NIL)
Total shares proposed for sale stand at 4,42,200 equity shares
Current market price cited in application is INR 177.00 per share (closing as of September 21, 2026)
Proposed trades to be executed through stock exchange within 7 days of approval
👀 What to Watch
Track subsequent insider trading disclosures (Form C) within 2-7 trading days to confirm if and at what volume the proposed promoter share sales are executed in the market.
TVS Motor Seeks Shareholder Nod to Appoint Peyman Kargar as Director & CEO for 5 Years
TVS Motor Company has issued a Postal Ballot notice seeking shareholder approval via ordinary resolutions to appoint Mr. Peyman Kargar as Director and Chief Executive Officer (in the rank of Whole-Time Director) for a five-year term starting 27th January 2027. Mr. Kargar brings over three decades of automotive sector experience across product planning, R&D, and manufacturing. The electronic voting window runs from 23rd September 2026 to 22nd October 2026, with results scheduled on or before 24th October 2026.
Confidence: HIGH
What changedTVS Motor has initiated the formal postal ballot process to confirm the appointment of Peyman Kargar as CEO & Whole-Time Director effective January 2027.
Why it mattersLeadership succession is critical for TVS Motor as it scales premium international markets and accelerates EV product rollouts across domestic and export geographies.
Tenure of Appointment: 5 (five) yearsEffective Appointment Date: 27th January 2027E-voting Start Date: 23rd September 2026E-voting End Date: 22nd October 2026
📅 Short termShareholders will vote on the ordinary resolution by 22nd October 2026; no immediate impact on day-to-day operations is expected prior to the effective date in January 2027.
📈 Long termA veteran automotive leader at the helm could aid TVS Motor's global expansion, Norton turnaround, and international EV distribution over his 5-year tenure.
⚠ Risk flags
- Subject to approval by shareholders and the Central Government
Key Highlights
Proposed appointment of Mr. Peyman Kargar as Director & CEO for a 5-year term effective 27th January 2027
E-voting period scheduled from 23rd September 2026 (9:00 AM IST) to 22nd October 2026 (5:00 PM IST)
Voting cut-off date set as Friday, 18th September 2026
Results of the postal ballot to be declared on or before Saturday, 24th October 2026
👀 What to Watch
Track the outcome of the postal ballot voting on 24th October 2026 and monitor future announcements regarding leadership transition and global strategy execution under the incoming CEO.
Embassy Developments raises ₹105 Cr via 12.50% unlisted NCDs
Embassy Developments Limited has approved the allotment of 10,500 rated, unlisted, secured, redeemable NCDs aggregating to ₹105 crore on a private placement basis. This forms part of a total approved issue size of up to ₹160 crore. The instruments carry a 12.50% per annum cash coupon payable semi-annually and have a tenure of 2 years, maturing on September 22, 2028. The issue adds to the company's existing debt load of ₹1,978 crore amid persistent operational losses.
Confidence: HIGH
What changedThe company issued ₹105 crore worth of 2-year secured NCDs out of an approved ₹160 crore limit.
Why it mattersProvides immediate liquidity for operational or project needs, but at a relatively high cost of capital (12.50% coupon), adding ₹13.1 crore in annual interest expense.
Issue size allotted: INR 105 croresTotal approved issue size: INR 160 croresCoupon rate: 12.50% per annumMaturity date: September 22, 2028Issue vs existing debt: ~5.3%
📅 Short termNear-term liquidity support for development requirements; minimal equity market impact given it is unlisted debt.
📈 Long termLimited structural impact, but refinancing high-cost debt (12.50%) with operating cash flows will depend on project deliveries and revenue recognition under Ind AS 115.
⚠ Risk flags
- High borrowing cost (12.50% p.a.) adds to recurring interest burdens
- Company reported negative TTM operating margins (-47.2%) and net losses
Key Highlights
Allotment of 10,500 NCDs aggregating to ₹105 crore on private placement basis
Carries a cash coupon of 12.50% p.a. payable semi-annually
Tenure of 2 years with maturity date set for September 22, 2028
Part of a total approved issue size of up to ₹160 crore
Secured by a charge on identified assets of the company and/or its subsidiaries
👀 What to Watch
Track the deployment of funds toward project execution and watch whether high interest obligations exacerbate quarterly net losses (TTM net loss at ₹944 crore).
Pramodini Medicare Acquires 30% Stake in Sidheart Advanced Healthcare for 10-Year OMT Project
Pramodini Medicare Limited has incorporated an associate entity, Sidheart Advanced Healthcare Private Limited, acquiring a 30% equity stake on September 21, 2026. The new entity will act as the concessionaire for an Operate, Maintain and Transfer (OMT) cardiac facility at Kodagu Institute of Medical Sciences, Karnataka, for a 10-year concession period. The facility includes a cardiac catheterisation laboratory, 20 beds (9 general and 11 cardiac care beds), cardiac OPD, and diagnostics under a PPP model. The initial investment made by the company stands at a nominal ₹30,000 for equity subscription.
Confidence: HIGH
What changedIncorporated a 30%-owned associate entity to operate a public-private partnership cardiac healthcare facility in Karnataka.
Why it mattersExpands Pramodini Medicare's reach into specialized hospital cardiac services under a guaranteed 10-year concession model.
Equity Stake Acquired: 30%Investment Amount: Rs. 30,000/-Authorized Share Capital: Rs. 10,00,000Concession Period: 10 (ten) yearsBed Capacity: 20 beds
📅 Short termLimited immediate financial impact due to the nominal initial equity investment, but positive for operational footprint expansion.
📈 Long termProvides steady, recurring operational revenue over a 10-year window once the cardiac lab and CCU facility commence operations.
⚠ Risk flags
- Execution and ramp-up risks typical of PPP healthcare projects
- Contractual conflict between share count (text states 3,000 shares vs 30,000 shares for 30%)
Key Highlights
Acquired 30% equity stake (30,000 shares / ₹30,000) in newly incorporated Sidheart Advanced Healthcare
Entity awarded 10-year Concession Agreement on Operate, Maintain and Transfer (OMT) mode via PPP model
Scope covers a cardiac facility with 20 beds (9 general ward, 11 CCU beds) and a cardiac catheterisation lab
Authorized share capital of the incorporated entity is ₹10,00,000
👀 What to Watch
Track execution timelines for the concession agreement signing and subsequent operational commissioning of the cardiac facility at Kodagu Institute of Medical Sciences.
Pramodini Medicare Acquires 30% Stake in Sidheart Advanced Healthcare for 10-Year OMT Project
Pramodini Medicare Limited has incorporated an associate entity, Sidheart Advanced Healthcare Private Limited, acquiring a 30% equity stake on September 21, 2026. The new entity will act as the concessionaire for an Operate, Maintain and Transfer (OMT) cardiac facility at Kodagu Institute of Medical Sciences, Karnataka, for a 10-year concession period. The facility includes a cardiac catheterisation laboratory, 20 beds (9 general and 11 cardiac care beds), cardiac OPD, and diagnostics under a PPP model. The initial investment made by the company stands at a nominal ₹30,000 for equity subscription.
Confidence: HIGH
What changedIncorporated a 30%-owned associate entity to operate a public-private partnership cardiac healthcare facility in Karnataka.
Why it mattersExpands Pramodini Medicare's reach into specialized hospital cardiac services under a guaranteed 10-year concession model.
Equity Stake Acquired: 30%Investment Amount: Rs. 30,000/-Authorized Share Capital: Rs. 10,00,000Concession Period: 10 (ten) yearsBed Capacity: 20 beds
📅 Short termLimited immediate financial impact due to the nominal initial equity investment, but positive for operational footprint expansion.
📈 Long termProvides steady, recurring operational revenue over a 10-year window once the cardiac lab and CCU facility commence operations.
⚠ Risk flags
- Execution and ramp-up risks typical of PPP healthcare projects
- Contractual conflict between share count (text states 3,000 shares vs 30,000 shares for 30%)
Key Highlights
Acquired 30% equity stake (30,000 shares / ₹30,000) in newly incorporated Sidheart Advanced Healthcare
Entity awarded 10-year Concession Agreement on Operate, Maintain and Transfer (OMT) mode via PPP model
Scope covers a cardiac facility with 20 beds (9 general ward, 11 CCU beds) and a cardiac catheterisation lab
Authorized share capital of the incorporated entity is ₹10,00,000
👀 What to Watch
Track execution timelines for the concession agreement signing and subsequent operational commissioning of the cardiac facility at Kodagu Institute of Medical Sciences.
Manba Finance to Raise up to ₹100 Crore via Preferential Issue of Shares and Warrants at ₹135
Manba Finance's board has approved a preferential issue of equity shares and convertible warrants to raise up to ₹99.99 crore at an issue price of ₹135 per security (including a ₹125 premium). The fundraise represents ~14.7% of its current market cap (₹680 crore) and ~24.4% of its net worth (₹410 crore). Of the total, ₹67.50 crore will be raised from public investors via 50.00 lakh equity shares, while ₹32.50 crore will be raised from promoters via 24.07 lakh warrants (25% payable upfront). Additionally, the board approved an increase in authorized share capital from ₹55 crore to ₹65 crore and re-appointed key management personnel.
Confidence: HIGH
What changedThe board approved a ₹100 crore capital raise via shares and promoter warrants at ₹135/share, alongside an authorized capital increase and executive re-appointments.
Why it mattersProvides fresh equity Tier-1 capital to support loan book growth, expand geographical presence, and lower leverage without changing operational management control.
Total fundraise value: ₹99,99,76,860Fundraise vs Market Cap: ~14.7%Fundraise vs Net Worth: ~24.4%Issue price per unit: ₹135Equity shares to public: 50,00,013Warrants to promoters: 24,07,223
📅 Short termThe issue price of ₹135 is roughly in line with the current market price of ₹136.4, providing price support as promoter commitment is demonstrated via warrant subscriptions.
📈 Long termStrengthens the balance sheet and capital adequacy, enabling Manba Finance to accelerate AUM expansion in target segments like EV and used vehicle financing.
⚠ Risk flags
- Equity dilution of ~74.07 lakh shares (~14.7% on current base) upon full conversion of warrants
- Subject to shareholder approval and regulatory clearances from stock exchanges
Key Highlights
Preferential issuance of securities aggregating up to ₹99,99,76,860 at ₹135 per unit (face value ₹10 + ₹125 premium)
Non-promoter/public investors allotted 50,00,013 equity shares aggregating up to ₹67.50 crore
Promoters allotted 24,07,223 convertible warrants aggregating up to ₹32.50 crore, exercisable within 18 months
Authorized share capital increased from ₹55 crore to ₹65 crore to accommodate the dilution
Proceeds to be utilized to meet funding requirements for lending and financing activities
👀 What to Watch
Track shareholder approval at the ensuing Extraordinary General Meeting (EGM) and stock exchange in-principle approvals for the preferential issue.
Manba Finance to Raise up to ₹100 Crore via Preferential Issue of Shares and Warrants at ₹135
Manba Finance's board has approved a preferential issue of equity shares and convertible warrants to raise up to ₹99.99 crore at an issue price of ₹135 per security (including a ₹125 premium). The fundraise represents ~14.7% of its current market cap (₹680 crore) and ~24.4% of its net worth (₹410 crore). Of the total, ₹67.50 crore will be raised from public investors via 50.00 lakh equity shares, while ₹32.50 crore will be raised from promoters via 24.07 lakh warrants (25% payable upfront). Additionally, the board approved an increase in authorized share capital from ₹55 crore to ₹65 crore and re-appointed key management personnel.
Confidence: HIGH
What changedThe board approved a ₹100 crore capital raise via shares and promoter warrants at ₹135/share, alongside an authorized capital increase and executive re-appointments.
Why it mattersProvides fresh equity Tier-1 capital to support loan book growth, expand geographical presence, and lower leverage without changing operational management control.
Total fundraise value: ₹99,99,76,860Fundraise vs Market Cap: ~14.7%Fundraise vs Net Worth: ~24.4%Issue price per unit: ₹135Equity shares to public: 50,00,013Warrants to promoters: 24,07,223
📅 Short termThe issue price of ₹135 is roughly in line with the current market price of ₹136.4, providing price support as promoter commitment is demonstrated via warrant subscriptions.
📈 Long termStrengthens the balance sheet and capital adequacy, enabling Manba Finance to accelerate AUM expansion in target segments like EV and used vehicle financing.
⚠ Risk flags
- Equity dilution of ~74.07 lakh shares (~14.7% on current base) upon full conversion of warrants
- Subject to shareholder approval and regulatory clearances from stock exchanges
Key Highlights
Preferential issuance of securities aggregating up to ₹99,99,76,860 at ₹135 per unit (face value ₹10 + ₹125 premium)
Non-promoter/public investors allotted 50,00,013 equity shares aggregating up to ₹67.50 crore
Promoters allotted 24,07,223 convertible warrants aggregating up to ₹32.50 crore, exercisable within 18 months
Authorized share capital increased from ₹55 crore to ₹65 crore to accommodate the dilution
Proceeds to be utilized to meet funding requirements for lending and financing activities
👀 What to Watch
Track shareholder approval at the ensuing Extraordinary General Meeting (EGM) and stock exchange in-principle approvals for the preferential issue.
Manba Finance to Raise up to ₹100 Crore via Preferential Issue of Shares and Warrants at ₹135
Manba Finance's board has approved a preferential issue of equity shares and convertible warrants to raise up to ₹99.99 crore at an issue price of ₹135 per security (including a ₹125 premium). The fundraise represents ~14.7% of its current market cap (₹680 crore) and ~24.4% of its net worth (₹410 crore). Of the total, ₹67.50 crore will be raised from public investors via 50.00 lakh equity shares, while ₹32.50 crore will be raised from promoters via 24.07 lakh warrants (25% payable upfront). Additionally, the board approved an increase in authorized share capital from ₹55 crore to ₹65 crore and re-appointed key management personnel.
Confidence: HIGH
What changedThe board approved a ₹100 crore capital raise via shares and promoter warrants at ₹135/share, alongside an authorized capital increase and executive re-appointments.
Why it mattersProvides fresh equity Tier-1 capital to support loan book growth, expand geographical presence, and lower leverage without changing operational management control.
Total fundraise value: ₹99,99,76,860Fundraise vs Market Cap: ~14.7%Fundraise vs Net Worth: ~24.4%Issue price per unit: ₹135Equity shares to public: 50,00,013Warrants to promoters: 24,07,223
📅 Short termThe issue price of ₹135 is roughly in line with the current market price of ₹136.4, providing price support as promoter commitment is demonstrated via warrant subscriptions.
📈 Long termStrengthens the balance sheet and capital adequacy, enabling Manba Finance to accelerate AUM expansion in target segments like EV and used vehicle financing.
⚠ Risk flags
- Equity dilution of ~74.07 lakh shares (~14.7% on current base) upon full conversion of warrants
- Subject to shareholder approval and regulatory clearances from stock exchanges
Key Highlights
Preferential issuance of securities aggregating up to ₹99,99,76,860 at ₹135 per unit (face value ₹10 + ₹125 premium)
Non-promoter/public investors allotted 50,00,013 equity shares aggregating up to ₹67.50 crore
Promoters allotted 24,07,223 convertible warrants aggregating up to ₹32.50 crore, exercisable within 18 months
Authorized share capital increased from ₹55 crore to ₹65 crore to accommodate the dilution
Proceeds to be utilized to meet funding requirements for lending and financing activities
👀 What to Watch
Track shareholder approval at the ensuing Extraordinary General Meeting (EGM) and stock exchange in-principle approvals for the preferential issue.
Manba Finance to Raise up to ₹100 Crore via Preferential Issue of Shares and Warrants at ₹135
Manba Finance's board has approved a preferential issue of equity shares and convertible warrants to raise up to ₹99.99 crore at an issue price of ₹135 per security (including a ₹125 premium). The fundraise represents ~14.7% of its current market cap (₹680 crore) and ~24.4% of its net worth (₹410 crore). Of the total, ₹67.50 crore will be raised from public investors via 50.00 lakh equity shares, while ₹32.50 crore will be raised from promoters via 24.07 lakh warrants (25% payable upfront). Additionally, the board approved an increase in authorized share capital from ₹55 crore to ₹65 crore and re-appointed key management personnel.
Confidence: HIGH
What changedThe board approved a ₹100 crore capital raise via shares and promoter warrants at ₹135/share, alongside an authorized capital increase and executive re-appointments.
Why it mattersProvides fresh equity Tier-1 capital to support loan book growth, expand geographical presence, and lower leverage without changing operational management control.
Total fundraise value: ₹99,99,76,860Fundraise vs Market Cap: ~14.7%Fundraise vs Net Worth: ~24.4%Issue price per unit: ₹135Equity shares to public: 50,00,013Warrants to promoters: 24,07,223
📅 Short termThe issue price of ₹135 is roughly in line with the current market price of ₹136.4, providing price support as promoter commitment is demonstrated via warrant subscriptions.
📈 Long termStrengthens the balance sheet and capital adequacy, enabling Manba Finance to accelerate AUM expansion in target segments like EV and used vehicle financing.
⚠ Risk flags
- Equity dilution of ~74.07 lakh shares (~14.7% on current base) upon full conversion of warrants
- Subject to shareholder approval and regulatory clearances from stock exchanges
Key Highlights
Preferential issuance of securities aggregating up to ₹99,99,76,860 at ₹135 per unit (face value ₹10 + ₹125 premium)
Non-promoter/public investors allotted 50,00,013 equity shares aggregating up to ₹67.50 crore
Promoters allotted 24,07,223 convertible warrants aggregating up to ₹32.50 crore, exercisable within 18 months
Authorized share capital increased from ₹55 crore to ₹65 crore to accommodate the dilution
Proceeds to be utilized to meet funding requirements for lending and financing activities
👀 What to Watch
Track shareholder approval at the ensuing Extraordinary General Meeting (EGM) and stock exchange in-principle approvals for the preferential issue.
Manba Finance to Raise up to ₹100 Crore via Preferential Issue of Shares and Warrants at ₹135
Manba Finance's board has approved a preferential issue of equity shares and convertible warrants to raise up to ₹99.99 crore at an issue price of ₹135 per security (including a ₹125 premium). The fundraise represents ~14.7% of its current market cap (₹680 crore) and ~24.4% of its net worth (₹410 crore). Of the total, ₹67.50 crore will be raised from public investors via 50.00 lakh equity shares, while ₹32.50 crore will be raised from promoters via 24.07 lakh warrants (25% payable upfront). Additionally, the board approved an increase in authorized share capital from ₹55 crore to ₹65 crore and re-appointed key management personnel.
Confidence: HIGH
What changedThe board approved a ₹100 crore capital raise via shares and promoter warrants at ₹135/share, alongside an authorized capital increase and executive re-appointments.
Why it mattersProvides fresh equity Tier-1 capital to support loan book growth, expand geographical presence, and lower leverage without changing operational management control.
Total fundraise value: ₹99,99,76,860Fundraise vs Market Cap: ~14.7%Fundraise vs Net Worth: ~24.4%Issue price per unit: ₹135Equity shares to public: 50,00,013Warrants to promoters: 24,07,223
📅 Short termThe issue price of ₹135 is roughly in line with the current market price of ₹136.4, providing price support as promoter commitment is demonstrated via warrant subscriptions.
📈 Long termStrengthens the balance sheet and capital adequacy, enabling Manba Finance to accelerate AUM expansion in target segments like EV and used vehicle financing.
⚠ Risk flags
- Equity dilution of ~74.07 lakh shares (~14.7% on current base) upon full conversion of warrants
- Subject to shareholder approval and regulatory clearances from stock exchanges
Key Highlights
Preferential issuance of securities aggregating up to ₹99,99,76,860 at ₹135 per unit (face value ₹10 + ₹125 premium)
Non-promoter/public investors allotted 50,00,013 equity shares aggregating up to ₹67.50 crore
Promoters allotted 24,07,223 convertible warrants aggregating up to ₹32.50 crore, exercisable within 18 months
Authorized share capital increased from ₹55 crore to ₹65 crore to accommodate the dilution
Proceeds to be utilized to meet funding requirements for lending and financing activities
👀 What to Watch
Track shareholder approval at the ensuing Extraordinary General Meeting (EGM) and stock exchange in-principle approvals for the preferential issue.
